Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo

Gene Therapy

Volumn 15, Issue 18, 2008, Pages 1287-1293

  Jayandharan, G R ^a   Zhong, L ^a,b   Li, B ^a   Kachniarz, B ^a,c   Srivastava, A ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FK 506 BINDING PROTEIN; GENE PRODUCT; PARVOVIRUS VECTOR; PROTEIN FKBP52; PROTEIN PHOSPHATASE 5; PROTEIN TYROSINE PHOSPHATASE; SERINE; THREONINE; THYROXINE; VIRUS DNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA STRAND; DNA SYNTHESIS; EXPRESSION VECTOR; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; T LYMPHOCYTE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS RECOMBINATION;

ANIMALS; CELL LINE; DEPENDOVIRUS; DNA, SINGLE-STRANDED; DNA, VIRAL; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HEPATOCYTES; HUMANS; LIVER; MICE; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 2; TRANSDUCTION, GENETIC; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; MURINAE;

EID: 51049086842     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.89     Document Type: Article

References (41)

1. Conlon TJ, Flotte TR. Recombinant adeno-associated virus vectors for gene therapy. Expert Opin Biol Ther 2004; 4: 1093-1101.
2. Marshall E. Gene therapy. Viral vectors still pack surprises. Science 2001; 294: 1640.
3. Berns KI, Giraud C. Biology of adeno-associated virus. Curr Top Microbiol Immunol 1996; 218: 1-23.
4. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992; 158: 97-129.
5. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
6. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
7. Mah C, Qing K, Khuntirat B, Ponnazhagan S, Wang XS, Kube DM et al. Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J Virol 1998; 72. 9835-9843.
8. Qing K, Khuntirat B, Mah C, Kube DM, Wang XS, Ponnazhagan S et al. Adeno-associated virus type 2-mediated gene transfer: Correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J Virol 1998; 72: 1593-1599.
9. Qing K, Li W, Zhong L, Tan M, Hansen J, Weigel-Kelley KA et al. Adeno-associated virus type 2-mediated gene transfer: Role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo. J Virol 2003; 77: 2741-2746.
10. Qing K, Wang XS, Kube DM, Ponnazhagan S, Bajpai A, Srivastava A. Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc Nalt Acad Sci USA 1997; 94: 10879-10884.
11. Zhong L, Chen L, Li Y, Qing K, Weigel-Kelley KA, Chan RJ et al. Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo. Mol Ther 2004; 10: 950-957.
12. Zhac, W, Wu J, Zhong L, Srivastava A. Adeno-associated virus 2-mediated gene transfer: Role of a cellular serine/threonine protein phosphatase in augmenting transduction efficiency. Gene Therapy 2007; 14 545-550.
13. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Therapy 2001; 8: 1248-1254.
14. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Therapy 2003; 10: 2105-2111.
15. Wu J, Zhao, W, zhong L, Han Z, Li B, Ma W et al. Self-complementary recombinant adeno-associated viral vectors: Packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther 2007; 18: 171-182.
16. Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: Impact of larger genomes on infectivity and postentry steps. J Virol 2005; 79: 9933-9944.
17. Qing K, Hansen J, Weigel-Kelley KA, Tan M, Zhou S, Srivastava A. Adeno-associated virus type 2-mediated gene transfer: Role of cellular FKBP52 protein in transgene expression. J Virol 2001; 75: 8968-8976.
18. Zhong L, Li W, Yang Z, Chen L, Li Y, Qing K et al. Improved transduction of primary nuirine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo. Gene Therapy 2004; 11 1165-1169.
19. Zhong L, Li W, Yang Z, Qing K, Tan M, Hansen J et al. Impaired nuclear transport and uncoating limit recombinant adeno-associated virus 2 vector-mediated transduction of primary murine hematopoietic cells. Hum Gene Ther. 2004; 15: 1207-1218.
20. Flotte TR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT, Baker DJ et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004; 15: 93-128.
21. Snyder RO, Francis J. Adeno-associated viral vectors for clinical gene transfer studies. Curr Gene Ther 2005; 5: 311-321.
22. Auricchio A, Hildinger M, O'Connor E, Gao GP, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001; 12: 71-76.
23. Kube DM, Srivastava A. Quantitative DNA slot blot analysis: Inhibition of DNA binding to membranes by magnesium ions. Nucleic Acids Res 1997; 25: 3375-3376.
24. Zhao W, Zhong L, Wu J, Chen L, Qing K, Weigel-Kelley KA et al. Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors. Virology 2006; 353: 283-293.
25. Ponnazhagan S, Mukherjee P, Yoder MC, Wang XS, Zhou SZ, Kaplan J et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 1997; 190: 203-210.
26. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
27. Nakai H, Storm TA, Kay MA. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 2000; 18: 527-532.
28. Chen SJ, Tazelaar J, Wilson JM. Selective repopulation of normal mouse liver by hepatocytes transduced in vivo with recombinant adeno-associated virus. Hum Gene Ther 2001; 12: 45-50.
29. Song S, Embury J, Laipis PJ, Berns KI, Crawford JM, Flotte 1R. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 2001; 8: 1299-1306.
30. Zhong L, Zhao W, Wu J, Li B, Zolotukhin S, Govindasamy L et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007; 15: 1323-1330.
31. FerTer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nudeocytoplasmic trafficking of HER-ligands (Review). Int J Mol Med 2007; 20: 3-10.
32. Shinohara ET, Geng L, Tan J, Chen H, Shir Y, Edwards E et al. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 2005; 65: 4987-4992.
33. Feclorov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock AN et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 2007; 104: 20523-20528.
34. McLeod HL, Brunton VG, Eckardt N, Lear MJ, Robins DJ, Workman P et al. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br J Cancer 1996; 74: 1714-1718.
35. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
36. Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B et al. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7 1145-1159.
37. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto, LB, McClel-and A et al Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
38. Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC et al A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001; 12: 1907-1916.
39. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002; 13 1349-1359.
40. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003, 101: 2963-2972.
41. Liao L, Dearth RK, Zhou S, Britton OL, Lee AV, Xu J. Liver-specific overexpression of the insuhn-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology 2006; 147: 3877-3888.